Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
E
185490
vs
K
KOSPI 200
Over the past 12 months, EyeGene Inc has underperformed KOSPI 200, delivering a return of -9% compared to KOSPI 200's +116% growth.
Stocks Performance
185490 vs KOSPI 200
Performance Gap
185490 vs KOSPI 200
Performance By Year
185490 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
EyeGene Inc
Glance View
EyeGene Inc is a South Korean biotechnology company focused on genetic testing and molecular diagnostics. It develops and sells test kits and related services that help doctors and laboratories detect inherited diseases, infectious diseases, and other medical conditions from patient samples. The company makes money by selling diagnostic products, reagents, and test services to hospitals, clinics, labs, and other healthcare customers. In this model, EyeGene sits in the middle of the healthcare chain: it turns lab science into practical tests that doctors use to make faster and more accurate decisions. What makes the business different is that it depends on specialized assay development, clinical validation, and regulatory know-how rather than mass-market consumer sales. That gives EyeGene a role as a niche supplier to the medical testing market, where product reliability and ease of use matter more than brand recognition.